Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Trial of Everolimus Replacing MMF/MP Acid by the RECOVAC Consortium to Increase VACcine Response in Kidney Transplant Patients

NCT05924685 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT05924685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05924685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Trial of Everolimus Replacing MMF/MP Acid by the RECOVAC Consortium to Increase VACcine Response in Kidney Transplant Patients
Lead sponsor
University Medical Center Groningen
Phase
Phase 4
Overall status
Completed
Start date
August 22, 2023
Completion date
February 27, 2024
Enrollment
110 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 vaccines, immunosuppression, vaccine response, varicella zoster vaccine